Articles with public access mandates - Fairooz KabbinavarLearn more
Not available anywhere: 3
Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma
T Klatte, C Anterasian, JW Said, M de Martino, FF Kabbinavar, ...
The Journal of urology 183 (6), 2143-2147, 2010
Mandates: US National Institutes of Health
Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience
FD Birkhäuser, AJ Pantuck, EN Rampersaud, X Wang, N Kroeger, ...
The Cancer Journal 19 (3), 189-196, 2013
Mandates: Swiss National Science Foundation
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors
J Sarantopoulos, S Goel, V Chung, P Munster, S Pant, MR Patel, J Infante, ...
Cancer chemotherapy and pharmacology 78, 921-927, 2016
Mandates: US National Institutes of Health
Available somewhere: 18
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
A Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ...
The Lancet 389 (10066), 255-265, 2017
Mandates: US National Institutes of Health
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
RS Herbst, Y Sun, WEE Eberhardt, P Germonpré, N Saijo, C Zhou, ...
The lancet oncology 11 (7), 619-626, 2010
Mandates: US National Institutes of Health
The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
DF McDermott, SC Cheng, S Signoretti, KA Margolin, JI Clark, JA Sosman, ...
Clinical Cancer Research 21 (3), 561-568, 2015
Mandates: US National Institutes of Health
Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005
Y Ji, C Rankin, S Grunberg, AE Sherrod, J Ahmadi, JJ Townsend, ...
Journal of Clinical Oncology 33 (34), 4093-4098, 2015
Mandates: US National Institutes of Health
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer
EB Garon, HR Christofk, W Hosmer, CD Britten, A Bahng, MJ Crabtree, ...
Journal of cancer research and clinical oncology 140, 443-452, 2014
Mandates: US National Institutes of Health
Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a …
TF Cloughesy, K Petrecca, T Walbert, N Butowski, M Salacz, J Perry, ...
JAMA oncology 6 (12), 1939-1946, 2020
Mandates: US National Institutes of Health
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials …
Q Shi, A De Gramont, A Grothey, J Zalcberg, B Chibaudel, HJ Schmoll, ...
Journal of Clinical Oncology 33 (1), 22-28, 2015
Mandates: US National Institutes of Health, Cancer Research UK
Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project
KM Sjoquist, LA Renfro, RJ Simes, NC Tebbutt, S Clarke, MT Seymour, ...
JNCI: Journal of the National Cancer Institute 110 (6), 638-648, 2018
Mandates: US National Institutes of Health, National Health and Medical Research …
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non–small-cell lung cancer
FR Hirsch, F Kabbinavar, T Eisen, R Martins, FM Schnell, R Dziadziuszko, ...
Journal of clinical oncology 29 (26), 3567-3573, 2011
Mandates: US National Institutes of Health
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy
B Shuch, J Said, JC LaRochelle, Y Zhou, G Li, T Klatte, F Pouliot, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
Mandates: US National Institutes of Health
Clinical calculator for early mortality in metastatic colorectal cancer: an analysis of patients from 28 clinical trials in the Aide et Recherche en Cancérologie Digestive Database
LA Renfro, RM Goldberg, A Grothey, A Sobrero, R Adams, MT Seymour, ...
Journal of Clinical Oncology 35 (17), 1929-1937, 2017
Mandates: US National Institutes of Health, Cancer Research UK
Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma
N Kroeger, DB Seligson, T Klatte, EN Rampersaud, FD Birkhäuser, ...
European urology 61 (5), 888-895, 2012
Mandates: Swiss National Science Foundation
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
MN Fishman, S Srinivas, RJ Hauke, RJ Amato, B Esteves, MM Cotreau, ...
European Journal of Cancer 49 (13), 2841-2850, 2013
Mandates: US National Institutes of Health
Dendritic Cell–Based Immunotherapy in Prevention and Treatment of Renal Cell Carcinoma: Efficacy, Safety, and Activity of Ad-GM· CAIX in Immunocompetent Mouse Models
FD Birkhäuser, RC Koya, C Neufeld, EN Rampersaud, X Lu, ED Micewicz, ...
Journal of Immunotherapy 36 (2), 102-111, 2013
Mandates: Swiss National Science Foundation, US National Institutes of Health
Evaluation of continuous tumor-size–based end points as surrogates for overall survival in randomized clinical trials in metastatic colorectal cancer
T Burzykowski, E Coart, ED Saad, Q Shi, DW Sommeijer, C Bokemeyer, ...
JAMA network open 2 (9), e1911750-e1911750, 2019
Mandates: US National Institutes of Health
Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: pooled analysis from the ARCAD database
J Franko, J Yin, RA Adams, J Zalcberg, J Fiskum, E Van Cutsem, ...
European Journal of Cancer 174, 142-152, 2022
Mandates: Cancer Research UK
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
J Yin, S Dawood, R Cohen, J Meyers, J Zalcberg, T Yoshino, M Seymour, ...
Therapeutic advances in medical oncology 13, 17588359211020547, 2021
Mandates: US National Institutes of Health, Cancer Research UK
Publication and funding information is determined automatically by a computer program